Continuing Medical Education
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
Credit Designation Statement
AACR has designated this live activity for a maximum of 18.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
CLAIMING CME CREDIT
Physicians and other health care professionals seeking AMA PRA Category 1 CreditsTM for this continuing medical education activity must complete the online CME Request for Credit Survey by Friday, June 19, 2015. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on the conference website at www.acceleratingworkshop.org (CME tab) and via email. Your CME certificate will be sent to you via email after the completion of the activity.
Statement of Educational Need, Target Audience, and Learning Objectives:
This course provides a comprehensive review of agent (including drugs and biological) development including pre-clinical and clinical evaluation, and regulatory procedures and endpoints required to bring discovery into clinical use that provide benefit to patients. Few individual investigators have this entire scope of this knowledge, and this workshop integrates this knowledge with real-life examples, and specifically illustrates the role that the community, including the investigator plays in the process from discovery and approvals and beyond. Only one agent is successfully produced for every 20 that enter into clinical evaluation. The goal of this workshop is to accelerate and increase efficiency in the development of anticancer agents by providing insight and guidance into the process to make better informed decisions about which agents are likely to have efficacy and a satisfactory safety profile. The workshop provides examples of success and real life solutions to the challenges of producing successful development plans and clinical trials with an aim of developing anticancer agents that benefit patients. The workshop provides an opportunity for dialogue between regulatory agencies, patient advocates and scientist-investigators including basic, translational, and clinical populations.
After participating in this CME activity, physician-scientists should be able to:
- Assess the key decision points in determining if an anticancer agent or combination has clinical benefit
- Follow regulatory agency guidelines in the development phase of anticancer agents
- Design and participate in oncology clinical trials, with a better understanding of endpoints and accrual goals
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this workshop.
QUESTIONS ABOUT CME?
Please contact the AACR Office of CME at (215) 440-9300 or firstname.lastname@example.org.